Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest Metformin Stories

2013-03-13 16:25:54

PITTSBURGH, March 13, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has entered into a settlement agreement with Shionogi Inc. and Andrx that will resolve patent litigation related to Metformin Hydrochloride Extended-release Tablets USP, 500 mg and 1000 mg. This product is the generic version of Shionogi's Fortamet(®), and is indicated as an adjunct to diet and exercise to lower blood glucose.(1) Under the terms of the...

2013-02-28 23:02:09

A 26-week, multi-center, multinational, open-label, 2-arm parallel, randomized, treat-to-target trial in insulin naive subjects with Type 2 Diabetes. The total duration of the trial is approximately 29 weeks consisting of a 2 week screening period, 26 weeks of treatment and a follow-up visit 1 week after treatment. Birmingham, Alabama (PRWEB) February 28, 2013 *Achieve Clinical Research conducts Clinical Trials in Birmingham, Alabama. For more information about getting started with a...

2013-02-26 16:27:11

NEWARK, Calif., Feb. 26, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at the Cowen and Company 33rd Annual Health Care Conference at the Boston Marriott Copley Place Hotel in Boston. The presentation at the Cowen conference is scheduled for 10:00 am EST (7:00 am PST) on Tuesday, March 5, 2013. The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording...

2013-02-19 08:33:10

PARIS, Feb. 19, 2013 /PRNewswire/ -- Sanofi (EURONEXT : SAN and NYSE : SNY) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for lixisenatide, the first once-daily prandial GLP-1 receptor agonist for the treatment of adults with type 2 diabetes mellitus. The acceptance of the lixisenatide NDA filing follows the February 1, 2013, European Commission approval of lixisenatide in the European Union. (Logo:...

2013-02-14 08:28:54

SAN DIEGO, Feb. 14, 2013 /PRNewswire/ -- Elcelyx Therapeutics announced today the closing of a $20 million Series C financing to fund development of product candidates NewMet(TM) for Type 2 diabetes and Lovidia(TM), an over-the-counter weight loss product. The financing was led by GSM Fund LLC, a fund dedicated to this single investment and managed by Rick Barry, who has been elected to the Elcelyx Board of Directors. All previous investors also participated in the round, including...

2013-02-13 16:26:49

NEWARK, Calif., Feb. 13, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will release fourth quarter fiscal year 2012 financial results after the market closes on Wednesday, February 20, 2013. The Company will host a conference call beginning at 4:30 pm Eastern time, 1:30 pm California time to discuss its results. Participants can access the call by dialing 877-317-6789 (United States) or 412-317-6789 (international). The conference call will also be...

2013-02-07 12:24:06

FORT LAUDERDALE, Fla., Feb. 7, 2013 /PRNewswire/ -- It's quite possible you may have someone in your family or know of someone who has a friend or loved one that has been diagnosed with Alzheimer's. According to an article in the March issue of Life Extension® Magazine, someone in America develops Alzheimer's every 68 seconds and that rate is projected to more than double by 2050, to one every 33 seconds. (Logo: http://photos.prnewswire.com/prnh/20120223/FL58611LOGO-b ) But just...

2013-01-31 08:31:02

CORAL SPRINGS, Florida, January 31, 2013 /PRNewswire/ -- Crown Marketing Pharmaceuticals (OTC: CWNM [http://finance.yahoo.com/q?s=cwnm&ql=1 ]) announced today that it has achieved positive in-vitro testing results of the most widely prescribed Diabetes drug commonly known as Metformin. Crown's Controlled Drug Delivery Device (CDDT) is less than half the size of the 500mg dosage tablet, and may reduce and ameliorate many of the gastrointestinal side effects of Metformin. The...

Diabetes Drug Holds Promise As Lung Cancer Cure
2013-01-30 11:03:59

Watch the video "Diabetes Drug Could Hold Promise For Lung Cancer Patients" Brett Smith for redOrbit.com - Your Universe Online Scientists have been enthusiastic about the potential use of widely available diabetes drugs to treat various types of cancer. A new study from The Salk Institute for Biological Studies and the David Geffen UCLA School of Medicine suggests that these metabolism-affecting drugs can decrease the size of lung tumors in mice and increase their chances for...

2013-01-07 08:29:15

INGELHEIM, Germany, Jan. 7, 2013 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced top-line results for four completed Phase III clinical trials for empagliflozin, an investigational sodium glucose co-transporter-2 (SGLT-2) inhibitor being studied for treatment of patients with type 2 diabetes (T2D). In all four studies, the primary efficacy endpoint, defined as significant change in HbA1c from baseline compared to placebo, was met with...